From Ideal to Real: Making Guideline-Based Treatment Decisions for Bladder Cancer in Every Care Setting
17th - 18th Jun 2026, 11:00pm (GMT)
Free, Online
Evolving Paradigms in Lung Cancer
14th - 15th Jul 2026, 11:00pm (GMT)
Série Synergy sur le mCRPC: La résistance aux inhibiteurs de la voie du récepteur des androgènes dans le mCRPC - Infographie
Resistencia al inhibidor de la vía del receptor de andrógenos en el cáncer de próstata resistente a la castración metastásico (CPRCm) - Infografía
mCRPC Synergy-Serie - Resistenz gegen Androgenrezeptor-Signalweg-Inhibitoren (ARPI) bei mCRPC - Infografik
Bladder Cancer Advocacy Network (BCAN) - Patient Educational Materials Flyer
Added 25 Mar 2026
Personalized Pathways: Confidence and Coordination in Biomarker-Guided Muscle-Invasive Bladder Cancer Care
mCRPC Synergy Series: Overcoming Resistance and Optimizing Pathways - Synergy Snapshot
Personalized Pathways Podcast: Confidence and Coordination in Biomarker-Guided Muscle-Invasive Bladder Cancer Care
Duration: 35m 28s
3 months ago
Personalized Pathways: Muscle Invasive Bladder Cancer Care 2026 - Patient Perspective
Duration: 15m 35s
Personalized Pathways: Muscle Invasive Bladder Cancer Care 2026 | Part 2: Coordinating ctDNA Testing Across the Care Continuum
Duration: 17m 58s
Personalized Pathways: Muscle Invasive Bladder Cancer Care 2026 | Part 3: Applying ctDNA Results to Guide Individualized Care
Duration: 15m 2s
Personalized Pathways: Muscle Invasive Bladder Cancer Care 2026 | Part 1: Understanding the Dual Role of ctDNA
Duration: 15m 7s
mCRPC Synergy Series: Overcoming Resistance and Optimizing Pathways - Patient Perspective
Duration: 17m 45s
Personalized Pathways: Muscle Invasive Bladder Cancer Care 2026
3rd Mar 2026, 12:30am (GMT)
Global mCRPC Synergy Series: Overcoming Resistance and Optimizing Pathways
25th Feb 2026, 2:00pm (GMT)
mCRPC Synergy Series: Overcoming Resistance and Optimizing Pathways | Part 4: Emerging Non-Chemo Options
Duration: 20m 30s
4 months ago
mCRPC Synergy Series: Overcoming Resistance and Optimizing Pathways | Part 3: Epigenetic Rationale
Duration: 15m 1s
mCRPC Synergy Series: Overcoming Resistance and Optimizing Pathways | Part 2: Sequencing After ARPI
Duration: 19m 45s
mCRPC Synergy Series: Overcoming Resistance and Optimizing Pathways | Part 1: Decoding Resistance Biology
Duration: 15m 12s
